Abstract
Purpose. To determine by pharmacodynamic (PD) analysis physiologically relevant parameters of the cellular kinetics of erythropoiesis in acute anemia.
Methods. The PD relationships among erythropoietin (EPO), reticulocyte, and RBC (Hb) responses were investigated in young adult sheep in acute anemia induced twice by two controlled phlebotomies separated by a 4-week recovery period.
Results. The phlebotomies resulted in rapid increases in plasma EPO, with maximal levels occurring at 3 to 8 days, followed by a reticulocyte response with a delay of 0.5 to 1.5 days. The Hb returned to prephlebotomy base line at the end of the 4-week recovery period. The EPO, reticulocyte count, and Hb responses were well described by a PK/PD model (r = 0.975) with the following cellular kinetics parameters: the lag time between EPO activation of erythroid progenitor cells and reticulocyte formation; the reticulocyte-to-RBC maturation time; the reticulocyte and Hb formation efficacy coefficients, quantifying EPO's efficacy in stimulating the formation of reticulocytes and Hb, respectively; the C50 PK/PD transduction parameter defined as the EPO level resulting in half the maximum rate of erythropoiesis.
Conclusion. Physiologically relevant cellular kinetics parameters can be obtained by an endogenous PK/PD analysis of phlebotomy data and are useful for elucidating the pathophysiologic etiology of various anemias.
Similar content being viewed by others
REFERENCES
S. H. Chapel, P. Veng-Pedersen, R. L. Schmidt, and J. A. Widness. A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J.Pharmacol.Exp.Ther. 295:346-351 (2000).
J. A. Widness, R. L. Schmidt, P. Veng-Pedersen, N. Modi, and S. T. Sawyer. A sensitive and specific erythropoietin immunoprecipitation assay: Application to pharmacokinetic studies. J.Lab.Clin.Med. 119:285-294 (1992).
C. Peters, M. K. Georgieff, P. A. de Alarcon, R. T. Cook, L. F. Burmeister, L. S. Lowe, and J. A. Widness. Effect of chronic erythropoietin administration on plasma iron in newborn lambs. Biol.Neonate 70:218-228 (1996).
M. K. Georgieff, R. L. Schmidt, M. M. Mills, W. J. Radmer, and J. A. Widness. Fetal iron and cytochrome c status after intrauterine hypoxemia and erythropoietin administration. Am.J.Physiol. 262:R485-R491 (1992).
J. W. Adamson, B. Torok-Storb, and N. Lin. Analysis of erythropoiesis by erythroid colony formation in culture. Blood Cells 4:89-103 (1978).
M. C. Mackey and P. Dormer. Continuous maturation of proliferating erythroid precursors. Cell Tissue Kinet. 15:381-392 (1982).
P. Veng-Pedersen. Curve fitting and modelling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J.Pharmacokinet.Biopharm. 5:513-531 (1977).
M. F. Hutchinson and F. R. deHoog. Smoothing noise data with spline functions. Numer.Math. 47:99-106 (1985).
D. M. Mock, G. L. Lankford, J. A. Widness, L. F. Burmeister, D. Kahn, and R. G. Strauss. Measurement of red cell survival using biotin-labeled red cells: validation against 51Cr-labeled red cells. Transfusion 39:156-162 (1999).
J. S. Kaufman, D. J. Reda, C. L. Fye, D. S. Goldfarb, W. G. Henderson, J. G. Kleinman, and C. A. Vaamonde. Subcutaneous compared with intravenous Epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N.Engl.J.Med. 339:578-583 (1998).
I. C. Macdougall, D. E. Roberts, G. A. Coles, and J. D. Williams. Clinical pharmacokinetics of Epoetin (recombinant human erythropoietin). Clin.Pharmacokinet. 20:99-113 (1991).
S. F. Lui, W. W. Chung, C. B. Leung, K. Chan, and K. N. Lai. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin.Nephrol. 33:47-51 (1990).
T. Salmonson, B. G. Danielson, and B. Wikstrom. Pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br.J.Clin.Pharmacol. 29:709-713 (1990).
W. H. Yoon, S. J. Park, I. C. Kim, and M. G. Lee. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res.Commun.Mol.Pathol.Pharmacol. 96:227-240 (1997).
A. Markham and H. M. Bryson. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49:232-254 (1995).
G. L. Wang and G. L. Semenza. General involvement of hypoxia-induced factor 1 in transcriptional response to hypoxia. Proc.Natl.Acad.Sci.USA 90:4304-4308 (1998).
K. Guillemin and M. A. Krasnow. The hypoxic response. Huffing and HITing. Cell 89:9-12 (1997).
C. A. Finch, L. A. Harker, and J. D. Cook. Kinetics of the formed elements of human blood. Blood 50:699-707 (1977).
E. Beutler, M. A. Lichtman, B. S. Coller, and T. J. Kipps. Williams Hematology, 5th ed. McGraw-Hill, New York (1995).
W. Krzyzanski, R. Ramakrishnan, and J. Jusko. Basic pharmaco-dynamic models for agents that alter production of natural cells. J.Pharmacokinet.Biopharm. 27:467-489 (2000).
H. Akaike. Automatic control: A new look at the statistical model identification. IEEE Trans.Control Theory 19:716-723 (1974).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Veng-Pederson, P., Chapel, S., Schmidt, P.R.L. et al. An Integrated Pharmacodynamic Analysis of Erythropoietin, Reticulocyte, and Hemoglobin Responses in Acute Anemia. Pharm Res 19, 1630–1635 (2002). https://doi.org/10.1023/A:1020797110836
Issue Date:
DOI: https://doi.org/10.1023/A:1020797110836